Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Cash from Investing Activities of $8.3 million for Q1 2026, up 102.43% year-over-year from $4.1 million in Q1 2025, and down 71.95% quarter-over-quarter from $29.5 million in Q4 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Cash from Investing Activities for 6 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 102.43% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $47.7 million (up 109.84% YoY), while the FY2025 annual figure was -$301.0 million, down 16.65% from the prior year.
- Cash from Investing Activities slipped to $8.3 million in Q1 2026 per JANX's latest filing, from $29.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $33.9 million in Q4 2024 and bottomed at -$340.4 million in Q1 2025.
- Historically, Cash from Investing Activities has averaged -$31.4 million across 5 years, with a median of $8.3 million in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 20405.88% — and 2024, when it plunged 1201.33%.
- Janux Therapeutics' Cash from Investing Activities stood at -$1.6 million in 2022, then jumped by 793.45% to $11.1 million in 2023, then surged by 205.01% to $33.9 million in 2024, then decreased by 12.92% to $29.5 million in 2025, then plunged by 71.95% to $8.3 million in 2026.
- Business Quant data shows JANX's Cash from Investing Activities at $8.3 million in Q1 2026, $29.5 million in Q4 2025, and $8.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -38.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.78 Mn |
| Mar 31, 2026 | 8.29 Mn |
| Dec 31, 2025 | 29.54 Mn |
| Sep 30, 2025 | 8.31 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | -340.39 Mn |
| Dec 31, 2024 | 33.93 Mn |
| Sep 30, 2024 | 12.67 Mn |
| Jun 30, 2024 | -190.89 Mn |
| Mar 31, 2024 | -113.74 Mn |
| Dec 31, 2023 | 11.12 Mn |
| Sep 30, 2023 | -61.45 Mn |
| Jun 30, 2023 | 17.87 Mn |
| Mar 31, 2023 | -8.74 Mn |
| Dec 31, 2022 | -1.60 Mn |
| Sep 30, 2022 | 19.76 Mn |
| Jun 30, 2022 | 9.04 Mn |
| Mar 31, 2022 | 31.07 Mn |
| Dec 31, 2021 | 7.33 Mn |
| Sep 30, 2021 | -205.54 Mn |